Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-312023-01-01falseNo description of principal activity43falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 11730312 2023-01-01 2023-12-31 11730312 2022-01-01 2022-12-31 11730312 2023-12-31 11730312 2022-12-31 11730312 c:Director2 2023-01-01 2023-12-31 11730312 d:CurrentFinancialInstruments 2023-12-31 11730312 d:CurrentFinancialInstruments 2022-12-31 11730312 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 11730312 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 11730312 d:ShareCapital 2023-12-31 11730312 d:ShareCapital 2022-12-31 11730312 d:RetainedEarningsAccumulatedLosses 2023-12-31 11730312 d:RetainedEarningsAccumulatedLosses 2022-12-31 11730312 c:OrdinaryShareClass1 2023-01-01 2023-12-31 11730312 c:OrdinaryShareClass1 2023-12-31 11730312 c:OrdinaryShareClass1 2022-12-31 11730312 c:OrdinaryShareClass2 2023-01-01 2023-12-31 11730312 c:OrdinaryShareClass2 2023-12-31 11730312 c:OrdinaryShareClass2 2022-12-31 11730312 c:OrdinaryShareClass3 2023-01-01 2023-12-31 11730312 c:OrdinaryShareClass3 2023-12-31 11730312 c:OrdinaryShareClass3 2022-12-31 11730312 c:FRS102 2023-01-01 2023-12-31 11730312 c:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 11730312 c:FullAccounts 2023-01-01 2023-12-31 11730312 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 11730312 e:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11730312









EF MEDICAL LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

 
EF MEDICAL LIMITED
REGISTERED NUMBER: 11730312

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

  

Current assets
  

Stocks
  
18,625
18,625

Debtors: amounts falling due within one year
 4 
129,530
18,931

Cash at bank and in hand
 5 
76,686
247,011

  
224,841
284,567

Creditors: amounts falling due within one year
 6 
(21,552)
(12,027)

Net current assets
  
 
 
203,289
 
 
272,540

Total assets less current liabilities
  
203,289
272,540

  

Net assets
  
203,289
272,540


Capital and reserves
  

Called up share capital 
 7 
510,000
510,000

Profit and loss account
  
(306,711)
(237,460)

  
203,289
272,540

Page 1

 
EF MEDICAL LIMITED
REGISTERED NUMBER: 11730312
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 19 August 2024.




Victor Fieldgrass
Director

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
EF MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

EF Medical Limited is a private company limited by shares and registered in England and Wales. The address of the registered office and principal place of business is 103 Hammersmith Road, London, W14 0QH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.4

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell.

Page 3

 
EF MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 4 (2022 - 3).


4.


Debtors

2023
2022
£
£


Amounts owed by group undertakings
2,100
18,462

Other debtors
127,000
-

Prepayments and accrued income
430
469

129,530
18,931



5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
76,686
247,011

76,686
247,011


Page 4

 
EF MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
127
8,769

Other taxation and social security
5,499
257

Other creditors
13,526
601

Accruals and deferred income
2,400
2,400

21,552
12,027



7.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



8,000 (2022 - 8,000) A Ordinary shares of £1.00 each
8,000
8,000
2,000 (2022 - 2,000) B Ordinary shares of £1.00 each
2,000
2,000
500,000 (2022 - 500,000) Preference shares of £1.00 each
500,000
500,000

510,000

510,000


 
Page 5